The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 17, 2012
Filed:
Jul. 08, 2011
Michael T. Nordsiek, Wayne, PA (US);
Sharon F. Levy, Philadelphia, PA (US);
James H. Lee, Devon, PA (US);
James H. Kulp, West Chester, PA (US);
Kodumudi S. Balaji, Lansdale, PA (US);
Tze-chiang Meng, Lino Lakes, MN (US);
Jason J. Wu, Wayne, PA (US);
Valyn S. Bahm, Phoenixville, PA (US);
Robert Babilon, Boyertown, PA (US);
Michael T. Nordsiek, Wayne, PA (US);
Sharon F. Levy, Philadelphia, PA (US);
James H. Lee, Devon, PA (US);
James H. Kulp, West Chester, PA (US);
Kodumudi S. Balaji, Lansdale, PA (US);
Tze-Chiang Meng, Lino Lakes, MN (US);
Jason J. Wu, Wayne, PA (US);
Valyn S. Bahm, Phoenixville, PA (US);
Robert Babilon, Boyertown, PA (US);
Medicis Pharmaceutical Corporation, Scottsdale, AZ (US);
Abstract
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ('FDA'), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ('FDA') for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.